Passa P, Gauville C, Bentz F, Assan R, Canivet J
Presse Med (1893). 1979 Dec 10;8(48):3951-5.
Six normal subjects and six normotensive insulin-dependent diabetics underwent two insulin hypoglycaemia tests after administration for three days of either a placebo or of acebutolol--a cardioselective beta-blocker--at a dose of 400 mg per day. The order in which the tests were performed was decided by random selection. Acebutolol suppressed the tachycardia which occurred as a reaction to hypoglycaemia but did not interfere with other warning symptoms and signs. In both normal subjects and diabetics, acebutolol neither worsened the initial hypoglycaemia nor did it delay a return to normal values. The increase in lactate levels following hypoglycaemia was not reduced by acebutolol but free fatty acid rebound was suppressed. Hormonal responses (glucagon, cortisol, growth hormone) were unaffected by the beta-blocker. If they are confirmed by long term studies, these results would suggest that acebutolol is safer to use than non-cardioselective beta-blockers in the treatment of coronary insufficiency and of hypertension in diabetics exposed to the risk of hypoglycaemia.
六名正常受试者和六名血压正常的胰岛素依赖型糖尿病患者，在服用三天安慰剂或每天剂量为400毫克的醋丁洛尔（一种心脏选择性β受体阻滞剂）后，接受了两次胰岛素低血糖测试。测试执行顺序通过随机选择确定。醋丁洛尔抑制了低血糖反应时出现的心动过速，但不干扰其他警示症状和体征。在正常受试者和糖尿病患者中，醋丁洛尔既没有使初始低血糖情况恶化，也没有延迟恢复到正常水平。醋丁洛尔没有降低低血糖后乳酸水平的升高，但抑制了游离脂肪酸的反跳。激素反应（胰高血糖素、皮质醇、生长激素）不受β受体阻滞剂影响。如果长期研究证实这些结果，那么这些结果将表明，在治疗有低血糖风险的糖尿病患者的冠状动脉功能不全和高血压时，使用醋丁洛尔比非心脏选择性β受体阻滞剂更安全。
